2.Aesthetic Rehabilitation with Nano- Ceramic Composite Material - Case Reports
Noor Hayati Azami ; Nora Sakina Mohd Noor ; Wei Pin Ngan ; Jovian Tze Yu Then ; Yeong Chee Teoh
Annals of Dentistry 2018;25(2):53-57
Aesthetic or cosmetic dentistry is one of the main areas of dental practice. Increasing demands of patients for
aesthetics has resulted in the development of several techniques for restoring the anterior teeth. Composite
resin restorations have become an integral part of contemporary restorative dentistry and can be called “star
of minimal invasion” due to its conservative concepts. The direct composite veneering allows restoring the
tooth in a natural way and preservation of sound tooth structure when compared to indirect restorations.
Before placement of direct composite veneers, a proper diagnosis, available treatment options, cost of
treatment, patient’s expectations and duration of treatment should be taken into consideration. This article
presents three case reports of aesthetic rehabilitation of anterior teeth using direct composite with
satisfactory outcome that mimic the natural dentition.
3.The role of PIVKA-II in hepatocellular carcinoma surveillance in an Asian population.
Wai Yoong NG ; Daniel Yan Zheng LIM ; Si Yu TAN ; Jason Pik Eu CHANG ; Thinesh Lee KRISHNAMOORTHY ; Chee Hooi LIM ; Damien Meng Yew TAN ; Victoria Sze Min EKSTROM ; George Boon Bee GOH ; Mark Chang Chuen CHEAH ; Rajneesh KUMAR ; Chin Pin YEO ; Chee Kiat TAN
Annals of the Academy of Medicine, Singapore 2023;52(2):108-110
4.Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.
Whay Kuang CHIA ; Simon ONG ; Han Chong TOH ; Siew Wan HEE ; Su Pin CHOO ; Donald Y H POON ; Miah Hiang TAY ; Chee Kiat TAN ; Wen Hsin KOO ; Kian Fong FOO
Annals of the Academy of Medicine, Singapore 2008;37(7):554-558
INTRODUCTIONAdvanced hepatocellular carcinoma (HCC) has a dismal prognosis and is notoriously chemo-resistant. We conducted a Phase II prospective study to evaluate the activity and tolerability of gemcitabine and cisplatin in chemo-naïve advanced hepatocellular carcinoma. The trial considered a "no further interest" response rate of 10% and a target response rate of 30%. Utilising a Simon's minimax two-stage design with a type I error of 0.05 and power of 80%, 25 subjects would be required. Fifteen patients would be needed in stage 1 and if fewer than 2 responses were observed, the trial would be stopped and lack of efficacy claimed.
MATERIALS AND METHODSPatients with advanced HCC, diagnosed based on histology or by World Health Organization (WHO) criteria, were administered gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on day 1 and day 8 of a 21-day schedule. Assessment of response based on computer tomography was performed after every 2 cycles of chemotherapy.
RESULTSThe trial was stopped early due to a lack of efficacy. A total of 15 patients were accrued. Twelve patients were hepatitis B positive and the other 3 patients were negative for both hepatitis B and C. Only 1 patient had a history of prior heavy alcohol use. Two patients had Child C liver cirrhosis, 5 patients had Child B cirrhosis, and the remaining 8 patients had Child A cirrhosis. This regime was well tolerated and there was only 1 patient who experienced grade IV toxicities. Only 5 of 15 patients experienced grade III toxicities (nausea and emesis, 1 patient; anemia, 1 patient; thrombocytopenia, 1 patient; and neutropaenia, 2 patients). Only 1 patient experienced a partial response to the combination of gemcitabine and cisplatin. A further 3 patients experienced stable disease and 11 patients progressed on chemotherapy. The median time to progression was 6 weeks. The progression-free curve showed a sharp descent in the initial part of the study, suggesting that many patients had disease progression after enrollment. The median overall survival was 18 weeks.
CONCLUSIONThe progression-free survival and overall survival in our study were extremely short. Based on the results of our phase 2 study, we are unable to recommend further studies utilising gemcitabine and cisplatin combination in patients with advanced HCC.
Adult ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Carcinoma, Hepatocellular ; drug therapy ; etiology ; Cisplatin ; administration & dosage ; Deoxycytidine ; administration & dosage ; analogs & derivatives ; Disease-Free Survival ; Female ; Humans ; Liver Neoplasms ; drug therapy ; etiology ; Male ; Middle Aged ; Prospective Studies ; Time Factors ; Treatment Outcome
5.Experience of a rapid access falls and syncope service at a teaching hospital in Kuala Lumpur
Gan Sin Yin ; Nor Izzati Saedon ; Sukanya Subramaniam ; Nor Fairuz Husna Alias ; Siti Sakinah Mohd Nasir ; Noor Fatin Izzati Abu Hashim ; Imran Zainal Abidin ; Chee Kok Han ; Jassie Teo Yeh Lin ; Tan Maw Pin
The Medical Journal of Malaysia 2017;72(4):203-208
6.Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort.
Natalie KOH ; Vera Jin-Ling GOH ; Chee Kiang TEOH ; Jin Shing HON ; Louis Loon Yee TEO ; Choon Pin LIM ; David SIM
Singapore medical journal 2021;62(7):359-361
7.Ministry of Health Clinical Practice Guidelines: Chronic Obstructive Pulmonary Disease.
Tow Keang LIM ; Cynthia B CHEE ; Patsy CHOW ; Gerald Sw CHUA ; Soo Kiang ENG ; Soon Keng GOH ; Kwee Keng KNG ; Wai Hing LIM ; Tze Pin NG ; Thun How ONG ; S T Angeline SEAH ; Hsien Yung TAN ; K H TEE ; Vimal PALANICHAMY ; Meredith T YEUNG
Singapore medical journal 2018;59(2):76-86
The Ministry of Health (MOH) has updated the Clinical Practice Guidelines on Chronic Obstructive Pulmonary Disease (COPD) to provide doctors and patients in Singapore with evidence-based treatment for COPD. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH Clinical Practice Guidelines on COPD, for the information of SMJ readers. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website: https://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/doctors/guidelines/cpg_medical.html. The recommendations should be used with reference to the full text of the guidelines. Following this article are multiple choice questions based on the full text of the guidelines.
Adult
;
Aged
;
Evidence-Based Medicine
;
Humans
;
Middle Aged
;
Palliative Care
;
Prevalence
;
Pulmonary Disease, Chronic Obstructive
;
diagnosis
;
therapy
;
Pulmonary Medicine
;
standards
;
Quality Improvement
;
Radiography, Thoracic
;
Risk Factors
;
Singapore
;
Steroids
;
therapeutic use